The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C
Stuart C. Gordon, Jane W. Fang, Ann L. Silverman, John G. McHutchison, Janice K. Albrecht – 30 December 2003 – We sought to determine whether pretreatment serum alanine aminotransferase (ALT) levels in patients with chronic hepatitis C virus (HCV) correlate with demographic features and other disease characteristics and whether these values influence response to therapy. A total of 1,744 patients with HCV received either interferon alfa‐2b and placebo or combination interferon alfa‐2b and ribavirin for 24 or 48 weeks.